Acute lymphoblastic leukemia (ALL) is the second most common acute leukemia in adults,
with an incidence of over 6500 cases per year in the United States alone. The hallmark of …

Although acute lymphoblastic leukemia is curable in one third of adult patients, results vary
greatly on account of different clinical, immunologic, and cytogenetic/genetic characteristics …

The NCCN Guidelines for Acute Lymphoblastic Leukemia (ALL) focus on the classification of
ALL subtypes based on immunophenotype and cytogenetic/molecular markers; risk …

Adults with relapsed B cell acute lymphoblastic leukemia (B-ALL) have a dismal prognosis.
Only those patients able to achieve a second remission with no minimal residual disease …

The estimated overall incidence of acute lymphoblastic leukaemia (ALL) and lymphoblastic
lymphoma in Europe is 1.28 per 100 000 individuals annually, with significant age-related …

In this study, we randomly compared high doses of the tyrosine kinase inhibitor imatinib
combined with reduced-intensity chemotherapy (arm A) to standard imatinib/hyperCVAD …

Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy.
Advancements in technology that enhance our understanding of the biology of the disease …

Purpose Blinatumomab, a bispecific single-chain antibody targeting the CD19 antigen, is a
member of a novel class of antibodies that redirect T cells for selective lysis of tumor cells. In …

The Philadelphia chromosome positive arm of the UKALLXII/ECOG2993 study for adult
acute lymphoblastic leukemia (ALL) enrolled 266 patients between 1993 and 2003 (pre …

Abstract Historically, Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia
(ALL) has been associated with poor outcomes, and allogeneic hematopoietic cell …